You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrimipramine
Accession NumberDB00726  (APRD00498)
TypeSmall Molecule
GroupsApproved
DescriptionTricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. [PubChem]
Structure
Thumb
Synonyms
10,11-dihydro-N,N,beta-Trimethyl-5H-dibenz[b,F]azepine-5-propanamine
5-(gamma-dimethylamino-beta-Methylpropyl)-10,11-dihydro-5H-dibenzo[b,F]azepine
5-[3-(dimethylamino)-2-Methylpropyl]-10,11-dihydro-5H-dibenz[b,F]azepine
beta-Methylimipramine
RP-7162
Sapilent
Trimeprimina
Trimeprimine
Trimeproprimine
Trimipramina
Trimipramine
Trimipraminum
External Identifiers
  • IF 6120
  • IL 6001
  • RP 7162
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-tripramine Tab 100mg BPtablet100 mgoralNovopharm Limited1991-12-312015-10-26Canada
Novo-tripramine Tab 25mg BPtablet25 mgoralNovopharm Limited1991-12-312015-10-26Canada
Novo-tripramine Tab 50mg BPtablet50 mgoralNovopharm Limited1991-12-312015-10-26Canada
Nu-trimipramine Tab 100mgtablet100 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-trimipramine Tab 12.5mgtablet12.5 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-trimipramine Tab 25mgtablet25 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Nu-trimipramine Tab 50mgtablet50 mgoralNu Pharm Inc1993-12-312012-09-04Canada
Rhotriminetablet12.5 mgoralSanofi Aventis Canada Inc1988-12-312006-07-28Canada
Rhotriminecapsule75 mgoralSanofi Aventis Canada Inc1988-12-312007-03-29Canada
Rhotriminetablet25 mgoralSanofi Aventis Canada Inc1988-12-312006-07-28Canada
Rhotriminetablet50 mgoralSanofi Aventis Canada Inc1988-12-312006-07-28Canada
Rhotriminetablet100 mgoralSanofi Aventis Canada Inc1988-12-312007-03-29Canada
Surmontilcapsule25 mg/1oralTeva Women's Health, Inc.1990-09-30Not applicableUs
Surmontilcapsule50 mg/1oralTeva Women's Health, Inc.1990-09-30Not applicableUs
Surmontiltablet50 mgoralSanofi Aventis Canada Inc1971-12-312006-07-28Canada
Surmontilcapsule100 mg/1oralTeva Women's Health, Inc.1990-09-30Not applicableUs
Surmontiltablet25 mgoralSanofi Aventis Canada Inc1964-12-312006-07-28Canada
Surmontil 100tablet100 mgoralAventis Pharma Inc1964-12-312005-08-01Canada
Surmontil 12.5tablet12.5 mgoralAventis Pharma Inc1968-12-312005-08-01Canada
Surmontil 75capsule75 mgoralAventis Pharma Inc1979-12-312005-08-01Canada
Trimipraminetablet100 mgoralAa Pharma Inc1987-12-31Not applicableCanada
Trimipraminetablet12.5 mgoralAa Pharma Inc1987-12-31Not applicableCanada
Trimipraminetablet25 mgoralAa Pharma Inc1987-12-31Not applicableCanada
Trimipraminetablet50 mgoralAa Pharma Inc1987-12-31Not applicableCanada
Trimipraminecapsule75 mgoralAa Pharma Inc1994-12-31Not applicableCanada
Trimipramine Tab 100mgtablet100 mgoralPro Doc Limitee1987-12-312010-07-13Canada
Trimipramine Tab 12.5mgtablet12.5 mgoralPro Doc Limitee1987-12-312009-07-23Canada
Trimipramine Tab 25mgtablet25 mgoralPro Doc Limitee1987-12-312010-07-13Canada
Trimipramine Tab 50mgtablet50 mgoralPro Doc Limitee1987-12-312010-07-13Canada
Trimipramine-75 - Cap 75mgcapsule75 mgoralPro Doc Limitee1995-12-312010-07-13Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-trimipraminecapsule75 mgoralApotex IncNot applicableNot applicableCanada
Apo-trimipraminetablet25 mgoralApotex IncNot applicableNot applicableCanada
Apo-trimipraminetablet50 mgoralApotex IncNot applicableNot applicableCanada
Apo-trimipraminetablet100 mgoralApotex IncNot applicableNot applicableCanada
Apo-trimipraminetablet12.5 mgoralApotex IncNot applicableNot applicableCanada
Trimipramine Maleatecapsule25 mg/1oralActavis Pharma, Inc.2011-11-21Not applicableUs
Trimipramine Maleatecapsule25 mg/1oralCross Medika s.a.2016-04-18Not applicableUs
Trimipramine Maleatecapsule50 mg/1oralActavis Pharma, Inc.2011-11-21Not applicableUs
Trimipramine Maleatecapsule50 mg/1oralCross Medika s.a.2016-04-18Not applicableUs
Trimipramine Maleatecapsule100 mg/1oralActavis Pharma, Inc.2011-10-21Not applicableUs
Trimipramine Maleatecapsule100 mg/1oralCross Medika s.a.2016-04-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HerphonalTemmler
SapilentExtractumPharma
StangylSanofi-Aventis
TrimiduraMylan dura
TrimineurinHexal
TripressMylan
TydamineAspen Pharmacare
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Trimipramine maleate
ThumbNot applicableDBSALT000969
Categories
UNII6S082C9NDT
CAS number739-71-9
WeightAverage: 294.4338
Monoisotopic: 294.209598842
Chemical FormulaC20H26N2
InChI KeyInChIKey=ZSCDBOWYZJWBIY-UHFFFAOYSA-N
InChI
InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3
IUPAC Name
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}-2-methylpropyl)dimethylamine
SMILES
CC(CN(C)C)CN1C2=CC=CC=C2CCC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Alkyldiarylamine
  • Azepine
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance
PharmacodynamicsTrimipramine is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: a1 and b1 receptors are sensitized, a2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.
Mechanism of actionTrimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Related Articles
AbsorptionRapid absorption
Volume of distributionNot Available
Protein binding93%-96% (to plasma proteins)
Metabolism

Hepatic

Route of eliminationNot Available
Half life11-18 hrs
ClearanceNot Available
ToxicitySide effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9739
Blood Brain Barrier+0.9861
Caco-2 permeable+0.8059
P-glycoprotein substrateSubstrate0.6559
P-glycoprotein inhibitor IInhibitor0.8838
P-glycoprotein inhibitor IIInhibitor0.8826
Renal organic cation transporterInhibitor0.7098
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6698
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9094
CYP450 3A4 inhibitorNon-inhibitor0.6132
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6083
Ames testNon AMES toxic0.8109
CarcinogenicityNon-carcinogens0.9021
BiodegradationNot ready biodegradable0.9886
Rat acute toxicity2.8709 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9065
hERG inhibition (predictor II)Inhibitor0.8271
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral75 mg
Tabletoral100 mg
Tabletoral12.5 mg
Tabletoral25 mg
Tabletoral50 mg
Capsuleoral100 mg/1
Capsuleoral25 mg/1
Capsuleoral50 mg/1
Prices
Unit descriptionCostUnit
Trimipramine maleate powder51.0USD g
Surmontil 100 mg capsule5.92USD capsule
Surmontil 50 mg capsule4.15USD capsule
Trimipramine Maleate 50 mg capsule3.27USD capsule
Trimipramine 50 mg capsule3.14USD capsule
Surmontil 25 mg capsule2.49USD capsule
Trimipramine 25 mg capsule1.92USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point45 °CPhysProp
water solubilitySlightly solubleNot Available
logP4.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.026 mg/mLALOGPS
logP4.67ALOGPS
logP4.76ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity95.02 m3·mol-1ChemAxon
Polarizability35.67 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4m-5790000000-53c724efbeeb45818f39View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN06AA06
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelDownload (152 KB)
MSDSDownload (75 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Trimipramine can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Trimipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-MethylenedioxyamphetamineTrimipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineTrimipramine may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Trimipramine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Trimipramine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Trimipramine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Trimipramine.
AbirateroneThe metabolism of Trimipramine can be decreased when combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Trimipramine.
AcenocoumarolTrimipramine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Trimipramine.
AcetophenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Trimipramine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Trimipramine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Trimipramine.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Trimipramine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Trimipramine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Trimipramine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Trimipramine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trimipramine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Trimipramine.
AlmotriptanThe risk or severity of adverse effects can be increased when Trimipramine is combined with Almotriptan.
AlogliptinThe serum concentration of Trimipramine can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Trimipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Trimipramine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trimipramine.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Trimipramine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Trimipramine.
AmiodaroneTrimipramine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Trimipramine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Trimipramine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Trimipramine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Trimipramine.
AmoxapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Amperozide.
AmphetamineTrimipramine may increase the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Trimipramine can be increased when it is combined with Amprenavir.
AnagrelideTrimipramine may increase the QTc-prolonging activities of Anagrelide.
Antithrombin III humanThe serum concentration of Trimipramine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Trimipramine can be increased when it is combined with Apixaban.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Trimipramine.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Trimipramine.
AprepitantThe serum concentration of Trimipramine can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Trimipramine can be increased when it is combined with Aprotinin.
ArbutamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Arformoterol.
ArgatrobanThe serum concentration of Trimipramine can be increased when it is combined with Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Trimipramine is combined with Aripiprazole.
ArmodafinilThe metabolism of Trimipramine can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Trimipramine.
ArtemetherTrimipramine may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Trimipramine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Trimipramine.
AsenapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Asenapine.
AsunaprevirThe serum concentration of Trimipramine can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Trimipramine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Trimipramine.
AtomoxetineThe metabolism of Trimipramine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Trimipramine.
AzaperoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Azaperone.
AzelastineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trimipramine.
AzithromycinTrimipramine may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Trimipramine.
BambuterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Bambuterol.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Trimipramine.
BatimastatThe serum concentration of Trimipramine can be increased when it is combined with Batimastat.
BedaquilineTrimipramine may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilThe serum concentration of Trimipramine can be increased when it is combined with Benazepril.
BenmoxinBenmoxin may increase the serotonergic activities of Trimipramine.
BenzamidineThe serum concentration of Trimipramine can be increased when it is combined with Benzamidine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Trimipramine.
BenzphetamineTrimipramine may increase the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Trimipramine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Trimipramine.
BetaxololThe metabolism of Trimipramine can be decreased when combined with Betaxolol.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Trimipramine.
BexaroteneThe serum concentration of Trimipramine can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Trimipramine is combined with Bifeprunox.
BivalirudinThe serum concentration of Trimipramine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Trimipramine can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Trimipramine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Trimipramine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Trimipramine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trimipramine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Trimipramine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Trimipramine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Trimipramine.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Trimipramine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Trimipramine.
BrompheniramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Trimipramine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trimipramine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trimipramine.
BupropionThe metabolism of Trimipramine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Trimipramine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trimipramine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Trimipramine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Trimipramine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Trimipramine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Trimipramine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trimipramine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Trimipramine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Trimipramine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Trimipramine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Trimipramine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Trimipramine.
CandoxatrilThe serum concentration of Trimipramine can be increased when it is combined with Candoxatril.
CapecitabineThe metabolism of Trimipramine can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Trimipramine can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Trimipramine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Trimipramine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Trimipramine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Trimipramine.
CariprazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trimipramine.
CaroxazoneCaroxazone may increase the serotonergic activities of Trimipramine.
CelecoxibThe metabolism of Trimipramine can be decreased when combined with Celecoxib.
CeliprololThe risk or severity of adverse effects can be increased when Trimipramine is combined with Celiprolol.
CeritinibThe serum concentration of Trimipramine can be increased when it is combined with Ceritinib.
CeritinibTrimipramine may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Trimipramine.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Trimipramine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Trimipramine.
ChloramphenicolThe metabolism of Trimipramine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trimipramine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Trimipramine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trimipramine.
ChloroquineTrimipramine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Trimipramine can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorphenamine.
ChlorphentermineTrimipramine may increase the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Trimipramine can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Trimipramine.
CholecalciferolThe metabolism of Trimipramine can be decreased when combined with Cholecalciferol.
ChymostatinThe serum concentration of Trimipramine can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Trimipramine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Trimipramine can be increased when it is combined with Cilazapril.
CimetidineThe metabolism of Trimipramine can be decreased when combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Trimipramine.
CinacalcetThe serum concentration of Trimipramine can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trimipramine.
CiprofloxacinTrimipramine may increase the QTc-prolonging activities of Ciprofloxacin.
CirazolineTrimipramine may increase the vasopressor activities of Cirazoline.
CisaprideTrimipramine may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Trimipramine.
CitalopramThe risk or severity of adverse effects can be increased when Trimipramine is combined with Citalopram.
CitalopramThe metabolism of Trimipramine can be decreased when combined with Citalopram.
ClarithromycinTrimipramine may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Trimipramine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Trimipramine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clenbuterol.
ClidiniumThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Trimipramine.
ClobazamThe metabolism of Trimipramine can be decreased when combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Trimipramine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Trimipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clomipramine.
ClomipramineThe metabolism of Trimipramine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clonazepam.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Trimipramine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Trimipramine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Trimipramine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trimipramine.
ClotrimazoleThe metabolism of Trimipramine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Clozapine.
ClozapineThe metabolism of Trimipramine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Trimipramine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Trimipramine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Trimipramine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trimipramine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Trimipramine.
ConivaptanThe serum concentration of Trimipramine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Trimipramine.
CrizotinibTrimipramine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Trimipramine can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Trimipramine.
CyclosporineThe metabolism of Trimipramine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Trimipramine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Trimipramine.
Dabigatran etexilateThe serum concentration of Trimipramine can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Trimipramine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Trimipramine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Trimipramine.
DantroleneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Trimipramine.
DapiprazoleThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trimipramine.
DarifenacinThe metabolism of Trimipramine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Trimipramine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Trimipramine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Trimipramine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Trimipramine.
DeferasiroxThe serum concentration of Trimipramine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Trimipramine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Trimipramine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Trimipramine.
DesipramineThe metabolism of Trimipramine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Trimipramine.
DexamethasoneThe serum concentration of Trimipramine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Trimipramine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trimipramine.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Trimipramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trimipramine.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Trimipramine.
DextroamphetamineTrimipramine may increase the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trimipramine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trimipramine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trimipramine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Trimipramine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Trimipramine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Trimipramine.
DicoumarolTrimipramine may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Trimipramine.
DifenoxinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Trimipramine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Trimipramine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trimipramine.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Trimipramine.
DihydroergotamineThe metabolism of Trimipramine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trimipramine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trimipramine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Trimipramine.
DiltiazemThe metabolism of Trimipramine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Trimipramine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Trimipramine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trimipramine.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Trimipramine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Trimipramine.
DisopyramideTrimipramine may increase the QTc-prolonging activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dobutamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Trimipramine.
DofetilideTrimipramine may increase the QTc-prolonging activities of Dofetilide.
DolasetronTrimipramine may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Trimipramine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Trimipramine.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Trimipramine.
DoxepinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Trimipramine.
DoxycyclineThe metabolism of Trimipramine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
DoxylamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Trimipramine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
DronedaroneThe metabolism of Trimipramine can be decreased when combined with Dronedarone.
DronedaroneTrimipramine may increase the QTc-prolonging activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Trimipramine.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Trimipramine.
DuloxetineThe metabolism of Trimipramine can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trimipramine.
EcabetThe serum concentration of Trimipramine can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Trimipramine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Trimipramine.
EdoxabanThe serum concentration of Trimipramine can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Trimipramine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Trimipramine is combined with Efavirenz.
ElafinThe serum concentration of Trimipramine can be increased when it is combined with Elafin.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Trimipramine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Trimipramine.
EliglustatTrimipramine may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Trimipramine can be decreased when combined with Eliglustat.
EnalaprilThe serum concentration of Trimipramine can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Trimipramine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Trimipramine can be increased when it is combined with Enalkiren.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Trimipramine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Trimipramine.
EnzalutamideThe serum concentration of Trimipramine can be decreased when it is combined with Enzalutamide.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Trimipramine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Trimipramine.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Trimipramine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ergonovine.
ErgotamineTrimipramine may increase the vasopressor activities of Ergotamine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Trimipramine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Trimipramine.
ErythromycinTrimipramine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Trimipramine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Trimipramine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Trimipramine can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Trimipramine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Trimipramine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Trimipramine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Trimipramine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Trimipramine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trimipramine.
EthanolTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Trimipramine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trimipramine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Trimipramine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Trimipramine.
EthotoinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ethotoin.
Ethyl biscoumacetateTrimipramine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Trimipramine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Trimipramine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trimipramine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Trimipramine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Trimipramine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Trimipramine.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Trimipramine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Trimipramine.
EtoperidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Trimipramine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Trimipramine.
EtravirineThe serum concentration of Trimipramine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Trimipramine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Trimipramine.
EzogabineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fenfluramine.
FenoterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trimipramine.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Trimipramine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Trimipramine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Trimipramine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Trimipramine.
FlecainideTrimipramine may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flibanserin.
FloxuridineThe metabolism of Trimipramine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Trimipramine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Trimipramine.
FlunarizineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Trimipramine.
FluorouracilThe metabolism of Trimipramine can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluoxetine.
FluoxetineThe metabolism of Trimipramine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trimipramine.
FluspirileneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Trimipramine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Trimipramine.
FluvastatinThe metabolism of Trimipramine can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Trimipramine can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Formoterol.
FosamprenavirThe serum concentration of Trimipramine can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Trimipramine can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Trimipramine can be increased when it is combined with Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Trimipramine.
FrovatriptanThe risk or severity of adverse effects can be increased when Trimipramine is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Trimipramine.
Fusidic AcidThe serum concentration of Trimipramine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Trimipramine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Trimipramine is combined with gabapentin enacarbil.
Gadobenic acidTrimipramine may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Trimipramine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Trimipramine.
GeldanamycinThe serum concentration of Trimipramine can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Trimipramine.
GemfibrozilThe metabolism of Trimipramine can be decreased when combined with Gemfibrozil.
GemifloxacinTrimipramine may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Trimipramine.
GM6001The serum concentration of Trimipramine can be increased when it is combined with GM6001.
GoserelinTrimipramine may increase the QTc-prolonging activities of Goserelin.
GranisetronTrimipramine may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Trimipramine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Trimipramine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Trimipramine.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Trimipramine.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Trimipramine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Trimipramine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Trimipramine.
HaloperidolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Haloperidol.
HaloperidolThe metabolism of Trimipramine can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Trimipramine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Trimipramine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Trimipramine.
HirulogThe serum concentration of Trimipramine can be increased when it is combined with Hirulog.
HydracarbazineHydracarbazine may increase the serotonergic activities of Trimipramine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Trimipramine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Trimipramine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trimipramine.
Hydroxyamphetamine hydrobromideTrimipramine may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
HydroxyzineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Trimipramine.
IbutilideTrimipramine may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Trimipramine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Iloperidone.
ImatinibThe metabolism of Trimipramine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Trimipramine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Trimipramine.
ImipramineThe metabolism of Trimipramine can be decreased when combined with Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Indacaterol.
IndalpineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Indalpine.
IndinavirThe serum concentration of Trimipramine can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Trimipramine.
IproclozideIproclozide may increase the serotonergic activities of Trimipramine.
IproniazidIproniazid may increase the serotonergic activities of Trimipramine.
IrbesartanThe metabolism of Trimipramine can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Trimipramine.
IsavuconazoniumThe metabolism of Trimipramine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Trimipramine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Trimipramine is combined with Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Trimipramine.
IsoflurophateThe serum concentration of Trimipramine can be increased when it is combined with Isoflurophate.
IsoniazidThe metabolism of Trimipramine can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Isoprenaline.
IsradipineThe metabolism of Trimipramine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Trimipramine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Trimipramine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Trimipramine.
IxazomibThe serum concentration of Trimipramine can be increased when it is combined with Ixazomib.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trimipramine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Trimipramine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trimipramine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Trimipramine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Trimipramine.
KetoconazoleThe metabolism of Trimipramine can be decreased when combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Trimipramine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Trimipramine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trimipramine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Trimipramine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Trimipramine.
LeflunomideThe metabolism of Trimipramine can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Trimipramine.
LenvatinibTrimipramine may increase the QTc-prolonging activities of Lenvatinib.
LepirudinThe serum concentration of Trimipramine can be increased when it is combined with Lepirudin.
LeuprolideTrimipramine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Trimipramine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Trimipramine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Trimipramine.
LevocabastineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levodopa.
LevofloxacinTrimipramine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trimipramine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trimipramine.
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Trimipramine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Trimipramine.
LinagliptinThe serum concentration of Trimipramine can be increased when it is combined with Linagliptin.
LinezolidLinezolid may increase the serotonergic activities of Trimipramine.
LinezolidThe risk or severity of adverse effects can be increased when Trimipramine is combined with Linezolid.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Trimipramine.
LiotrixLiotrix may increase the arrhythmogenic activities of Trimipramine.
LisdexamfetamineTrimipramine may increase the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Trimipramine can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Trimipramine.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Trimipramine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Trimipramine.
LopinavirThe serum concentration of Trimipramine can be increased when it is combined with Lopinavir.
LopinavirTrimipramine may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Trimipramine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trimipramine.
LorcaserinThe metabolism of Trimipramine can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Trimipramine.
LosartanThe metabolism of Trimipramine can be decreased when combined with Losartan.
LovastatinThe metabolism of Trimipramine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Trimipramine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Trimipramine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Trimipramine can be decreased when it is combined with Lumacaftor.
LumefantrineTrimipramine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Trimipramine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Trimipramine.
MaprotilineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Maprotiline.
MebanazineMebanazine may increase the serotonergic activities of Trimipramine.
MeclizineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Trimipramine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Trimipramine.
MelperoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Melperone.
MephentermineTrimipramine may increase the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trimipramine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trimipramine.
MesoridazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Mesoridazine.
MetaraminolTrimipramine may increase the vasopressor activities of Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trimipramine.
MethadoneTrimipramine may increase the QTc-prolonging activities of Methadone.
MethadoneThe metabolism of Trimipramine can be decreased when combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Trimipramine.
MethamphetamineTrimipramine may increase the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Trimipramine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Trimipramine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trimipramine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Trimipramine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Trimipramine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methotrimeprazine.
MethoxamineTrimipramine may increase the vasopressor activities of Methoxamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Trimipramine.
MethsuximideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methsuximide.
Methylene blueTrimipramine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Trimipramine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Trimipramine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Trimipramine.
MetoclopramideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Trimipramine.
MetoprololThe metabolism of Trimipramine can be decreased when combined with Metoprolol.
MetyrosineTrimipramine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Trimipramine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Trimipramine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Trimipramine.
MidodrineTrimipramine may increase the vasopressor activities of Midodrine.
MifepristoneThe metabolism of Trimipramine can be decreased when combined with Mifepristone.
MifepristoneTrimipramine may increase the QTc-prolonging activities of Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Trimipramine is combined with Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Trimipramine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Trimipramine.
MirabegronThe metabolism of Trimipramine can be decreased when combined with Mirabegron.
MirtazapineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Trimipramine.
MitotaneThe serum concentration of Trimipramine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Trimipramine.
MoclobemideMoclobemide may increase the serotonergic activities of Trimipramine.
MoclobemideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Moclobemide.
ModafinilThe serum concentration of Trimipramine can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Trimipramine can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Trimipramine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Trimipramine.
MoxifloxacinTrimipramine may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Trimipramine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Trimipramine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Trimipramine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.
NabiloneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Trimipramine.
NafcillinThe serum concentration of Trimipramine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trimipramine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Trimipramine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Trimipramine.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Trimipramine.
NaratriptanThe risk or severity of adverse effects can be increased when Trimipramine is combined with Naratriptan.
NCX 4016The serum concentration of Trimipramine can be increased when it is combined with NCX 4016.
NefazodoneThe metabolism of Trimipramine can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Nefazodone.
NelfinavirThe serum concentration of Trimipramine can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Trimipramine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Trimipramine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Trimipramine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Trimipramine.
NicardipineThe metabolism of Trimipramine can be decreased when combined with Nicardipine.
NicorandilTrimipramine may increase the hypotensive activities of Nicorandil.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Trimipramine.
NilotinibThe metabolism of Trimipramine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Trimipramine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Trimipramine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Trimipramine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Trimipramine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Trimipramine.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Trimipramine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Trimipramine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trimipramine.
OctamoxinOctamoxin may increase the serotonergic activities of Trimipramine.
OfloxacinTrimipramine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olanzapine.
OlaparibThe metabolism of Trimipramine can be decreased when combined with Olaparib.
OlodaterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olodaterol.
OlopatadineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Olopatadine.
OmapatrilatThe serum concentration of Trimipramine can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Trimipramine.
OmeprazoleThe metabolism of Trimipramine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Trimipramine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Trimipramine.
OrciprenalineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Orciprenaline.
OrphenadrineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Trimipramine.
OsanetantThe risk or severity of adverse effects can be increased when Trimipramine is combined with Osanetant.
OsimertinibThe serum concentration of Trimipramine can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Trimipramine can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trimipramine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trimipramine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Trimipramine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trimipramine.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trimipramine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trimipramine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Trimipramine.
PalbociclibThe serum concentration of Trimipramine can be increased when it is combined with Palbociclib.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Trimipramine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Trimipramine.
PalonosetronPalonosetron may increase the serotonergic activities of Trimipramine.
PanobinostatTrimipramine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Trimipramine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Trimipramine can be decreased when combined with Pantoprazole.
ParaldehydeTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Trimipramine.
PargylinePargyline may increase the serotonergic activities of Trimipramine.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Trimipramine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Trimipramine.
Peginterferon alfa-2bThe serum concentration of Trimipramine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineTrimipramine may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trimipramine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trimipramine.
PerampanelThe risk or severity of adverse effects can be increased when Trimipramine is combined with Perampanel.
PerflutrenTrimipramine may increase the QTc-prolonging activities of Perflutren.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Trimipramine.
PerindoprilThe serum concentration of Trimipramine can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Trimipramine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trimipramine.
PhenelzinePhenelzine may increase the serotonergic activities of Trimipramine.
PhenelzineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Phenelzine.
PhenindioneTrimipramine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Trimipramine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Trimipramine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trimipramine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Trimipramine.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Trimipramine.
PhenprocoumonTrimipramine may increase the anticoagulant activities of Phenprocoumon.
PhentermineTrimipramine may increase the stimulatory activities of Phentermine.
PhenylephrineTrimipramine may increase the vasopressor activities of Phenylephrine.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Trimipramine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Trimipramine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Trimipramine.
PhosphoramidonThe serum concentration of Trimipramine can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pirbuterol.
PirlindolePirlindole may increase the serotonergic activities of Trimipramine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Trimipramine.
PivhydrazinePivhydrazine may increase the serotonergic activities of Trimipramine.
PizotifenThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Trimipramine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Trimipramine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Trimipramine.
PosaconazoleThe metabolism of Trimipramine can be decreased when combined with Posaconazole.
PramipexoleTrimipramine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Trimipramine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Trimipramine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Trimipramine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Trimipramine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Trimipramine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Trimipramine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trimipramine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Trimipramine.
PrimaquineTrimipramine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Primidone.
PrinomastatThe serum concentration of Trimipramine can be increased when it is combined with Prinomastat.
ProcainamideTrimipramine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Trimipramine.
ProcarbazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Procarbazine.
ProcaterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Trimipramine.
PromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Promazine.
PromazineThe metabolism of Trimipramine can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Promethazine.
PropafenoneTrimipramine may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trimipramine.
PropericiazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Trimipramine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Trimipramine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Trimipramine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trimipramine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Trimipramine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Trimipramine.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Trimipramine.
PyrimethamineThe metabolism of Trimipramine can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Trimipramine.
QuetiapineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Quetiapine.
QuinaprilThe serum concentration of Trimipramine can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Trimipramine.
QuinidineThe metabolism of Trimipramine can be decreased when combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Trimipramine.
QuinineThe metabolism of Trimipramine can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ramelteon.
RamiprilThe serum concentration of Trimipramine can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Trimipramine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Trimipramine.
RanolazineThe metabolism of Trimipramine can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Trimipramine.
RasagilineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trimipramine.
RemikirenThe serum concentration of Trimipramine can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Reserpine.
RifabutinThe metabolism of Trimipramine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Trimipramine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Trimipramine.
RifapentineThe metabolism of Trimipramine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Trimipramine.
RisperidoneThe therapeutic efficacy of Risperidone can be decreased when used in combination with Trimipramine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Trimipramine.
RitodrineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ritodrine.
RitonavirThe serum concentration of Trimipramine can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Trimipramine can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Trimipramine is combined with Rizatriptan.
RolapitantThe metabolism of Trimipramine can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Trimipramine.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Trimipramine.
RopiniroleTrimipramine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Trimipramine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trimipramine.
RotigotineTrimipramine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trimipramine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Trimipramine.
SafrazineSafrazine may increase the serotonergic activities of Trimipramine.
SalbutamolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Salbutamol.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Trimipramine.
SalmeterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Salmeterol.
SaquinavirThe serum concentration of Trimipramine can be increased when it is combined with Saquinavir.
SaquinavirTrimipramine may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Trimipramine can be increased when it is combined with Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trimipramine.
SelegilineSelegiline may increase the serotonergic activities of Trimipramine.
SelegilineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Trimipramine.
SertindoleThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sertraline.
SertralineThe metabolism of Trimipramine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trimipramine.
SildenafilThe metabolism of Trimipramine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Trimipramine.
SiltuximabThe serum concentration of Trimipramine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Trimipramine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Trimipramine can be increased when it is combined with Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Trimipramine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Trimipramine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Trimipramine.
SorafenibThe metabolism of Trimipramine can be decreased when combined with Sorafenib.
SotalolTrimipramine may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Trimipramine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Trimipramine.
SpiraprilThe serum concentration of Trimipramine can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Trimipramine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trimipramine.
SulfadiazineThe metabolism of Trimipramine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Trimipramine can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleTrimipramine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Trimipramine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Trimipramine.
SuvorexantThe risk or severity of adverse effects can be increased when Trimipramine is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Trimipramine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Trimipramine.
TapentadolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Trimipramine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Trimipramine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Trimipramine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Trimipramine can be increased when it is combined with Telaprevir.
TelavancinTrimipramine may increase the QTc-prolonging activities of Telavancin.
TelithromycinTrimipramine may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Trimipramine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Trimipramine.
TemocaprilThe serum concentration of Trimipramine can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Trimipramine.
TerbinafineThe metabolism of Trimipramine can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Terbutaline.
TetrabenazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Trimipramine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Trimipramine.
ThalidomideTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Trimipramine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Trimipramine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Trimipramine.
ThioproperazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Thioridazine.
ThiorphanThe serum concentration of Trimipramine can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Thiothixene.
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Trimipramine.
TiagabineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Trimipramine.
TicagrelorThe metabolism of Trimipramine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Trimipramine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Trimipramine.
TimololThe serum concentration of Timolol can be increased when it is combined with Trimipramine.
TipranavirThe serum concentration of Trimipramine can be increased when it is combined with Tipranavir.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Trimipramine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Trimipramine.
TocilizumabThe serum concentration of Trimipramine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Trimipramine can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Trimipramine.
ToloxatoneToloxatone may increase the serotonergic activities of Trimipramine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Trimipramine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Trimipramine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Trimipramine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Trimipramine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Trimipramine.
TrandolaprilThe serum concentration of Trimipramine can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Trimipramine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Trimipramine.
TranylcypromineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Trimipramine.
TrazodoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Trimipramine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Triflupromazine.
TrimethoprimThe metabolism of Trimipramine can be decreased when combined with Trimethoprim.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Trimipramine.
UbenimexThe serum concentration of Trimipramine can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Trimipramine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Trimipramine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Trimipramine.
ValsartanThe metabolism of Trimipramine can be decreased when combined with Valsartan.
VandetanibTrimipramine may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Trimipramine.
VemurafenibTrimipramine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Trimipramine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Trimipramine.
VerapamilThe metabolism of Trimipramine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Trimipramine.
VigabatrinThe risk or severity of adverse effects can be increased when Trimipramine is combined with Vigabatrin.
VilanterolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Vilanterol.
VilazodoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Vilazodone.
VildagliptinThe serum concentration of Trimipramine can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Trimipramine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Trimipramine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Trimipramine.
VoriconazoleThe metabolism of Trimipramine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Vortioxetine.
WarfarinTrimipramine may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Trimipramine can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Trimipramine.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Trimipramine.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Trimipramine.
ZafirlukastThe metabolism of Trimipramine can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trimipramine.
ZiconotideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Trimipramine.
ZimelidineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ziprasidone.
ZiprasidoneThe metabolism of Trimipramine can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Trimipramine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trimipramine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Trimipramine.
ZonisamideThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Trimipramine.
ZotepineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Diamond M, Kelly JP, Connor TJ: Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. Epub 2006 Jan 4. [PubMed:16388933 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
desensitize the target
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Components:
NameUniProt IDDetails
Muscarinic acetylcholine receptor M1P11229 Details
Muscarinic acetylcholine receptor M2P08172 Details
Muscarinic acetylcholine receptor M3P20309 Details
Muscarinic acetylcholine receptor M4P08173 Details
Muscarinic acetylcholine receptor M5P08912 Details
References
  1. Eikmeier G, Muszynski K, Berger M, Gastpar M: High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial. Pharmacopsychiatry. 1990 Sep;23(5):212-4. [PubMed:1979173 ]
Kind
Protein
Organism
Rat
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
Htr2c
Uniprot ID:
P08909
Molecular Weight:
51916.005 Da
References
  1. Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives. Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9. [PubMed:8863001 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23